0HOH Stock Overview
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
bluebird bio, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.98 |
52 Week High | US$5.53 |
52 Week Low | US$0.86 |
Beta | 0.80 |
1 Month Change | -16.02% |
3 Month Change | -7.30% |
1 Year Change | -80.50% |
3 Year Change | -96.64% |
5 Year Change | -99.32% |
Change since IPO | -99.51% |
Recent News & Updates
Recent updates
Shareholder Returns
0HOH | GB Biotechs | GB Market | |
---|---|---|---|
7D | 7.2% | 4.0% | 2.7% |
1Y | -80.5% | -23.5% | 5.2% |
Return vs Industry: 0HOH underperformed the UK Biotechs industry which returned -23.3% over the past year.
Return vs Market: 0HOH underperformed the UK Market which returned 4.5% over the past year.
Price Volatility
0HOH volatility | |
---|---|
0HOH Average Weekly Movement | 15.8% |
Biotechs Industry Average Movement | 8.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0HOH's share price has been volatile over the past 3 months.
Volatility Over Time: 0HOH's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 323 | Andrew Obenshain | www.bluebirdbio.com |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.
bluebird bio, Inc. Fundamentals Summary
0HOH fundamental statistics | |
---|---|
Market cap | US$194.67m |
Earnings (TTM) | -US$91.17m |
Revenue (TTM) | US$21.73m |
8.6x
P/S Ratio-2.1x
P/E RatioIs 0HOH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0HOH income statement (TTM) | |
---|---|
Revenue | US$21.73m |
Cost of Revenue | US$255.71m |
Gross Profit | -US$233.98m |
Other Expenses | -US$142.81m |
Earnings | -US$91.17m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 09, 2024
Earnings per share (EPS) | -0.47 |
Gross Margin | -1,076.97% |
Net Profit Margin | -419.62% |
Debt/Equity Ratio | 0% |
How did 0HOH perform over the long term?
See historical performance and comparison